News

A Phase 1 clinical trial evaluating the safety and preliminary efficacy of Sana Biotechnology’s candidate CAR T-cell therapy SC291 in adults with ANCA-associated vasculitis (AAV) and other autoimmune diseases has started enrollment. The study, GLEAM (NCT06294236), is recruiting up to 36 patients ranging in age from 18…

Rituximab is superior to other immunosuppressive treatments at preventing post-surgery relapse in granulomatosis with polyangiitis (GPA) patients undergoing surgery to address subglottic stenosis, a common complication that causes airway narrowing. That’s according to a study that analyzed data from 25 GPA patients who were followed for more than…

Amgen is planning to launch a Phase 3 clinical trial testing Tavneos (avacopan) — its approved therapy for adults with ANCA-associated vasculitis (AAV) — in combination with a standard regimen of rituximab or cyclophosphamide in children and adolescents with active AAV. That’s according to a company press release…

May will be an activity-filled month for people living with vasculitis — and for doctors, researchers, and advocates in the field — as the world recognizes Vasculitis Awareness Month (VAM), and International Vasculitis Day on May 15. Vasculitis is a group of rare autoimmune diseases characterized by inflammation and damage…

Lower blood counts of platelets — tiny cell fragments involved in blood clotting — at the time that ANCA-associated vasculitis (AAV) is diagnosed may be a marker of poorer kidney function and a higher risk of kidney failure, according to a retrospective study from China. Findings suggest that “platelet…

Men with ANCA-associated vasculitis (AAV) are three times more likely to develop cancer, most often that affecting the lungs and the head and neck, than age-matched men in the Turkish population, a study based on patient registry data found. Older age — age 60 or older — at AAV…

The risk of poor outcomes after a kidney transplant is considerably higher for ANCA-associated vasculitis (AAV) patients with kidney failure than people without the autoimmune disease, ranging from infections and disease relapse to death, a review study reports. But long-term survival rates for those who make it through the…

Tavneos (avacopan) safely and effectively promotes clinical remission in people with newly diagnosed or relapsing ANCA-associated vasculitis (AAV), according to a multicenter, real-world study in the U.S. The remission rates after a year of treatment were higher than those in the Phase 3 ADVOCATE trial (NCT02994927), whose…

Sinonasal symptoms, as assessed with 22-item Sinonasal Outcome Test (SNOT-22), a patient-reported questionnaire, are more severe when ANCA-associated vasculitis (AAV) is active than during remission, a study shows. Sinonasal symptoms are those that affect the nose and the sinuses, that is, the air-filled cavities around the eyes and nose.

Patrys’ PAT-DX1 and PAT-DX3, two DNA-targeting antibodies known as deoxymabs, can suppress production of the antimicrobial webs implicated in ANCA-associated vasculitis (AAV) without weakening other immune responses, according to preclinical work. These webs, called neutrophil extracellular traps (NETs), are made up of a scaffold of DNA and enzymes…